Full-Time
Laboratory Associate 1
Pre-clinical Team
Posted on 9/19/2025
Synthego
51-200 employees
Supplies synthetic RNA and gene-editing tools.
Compensation Overview
$26 - $28/hr
San Carlos, CA, USA
In Person
 Lab & Research (1) |
|---|
- Degree required/preferred AA in Chemistry, Biotech Certification, or in lieu of degree relevant work experience
- Self starter who is comfortable working with standard operating procedures
- Demonstrates a high level of integrity and accountability
- Demonstrates ability to work independently and as part of a team, to meet departmental goals
- Desire to work in a fast-paced, collaborative startup environment with a strong commitment to quality
- Strong written and verbal communication skills
- Excellent problem-solving skills
- Able to multi-task and prioritize work effectively
- Must be able to lift/move up to 25 pounds
- Must be able to sit and/or stand for extended periods up to four (4) hours at a time
- Responsible for synthesizing oligonucleotides by following established SOP’s which consists of but not limited to:
- Operate complex robotic systems to manage liquid product through a highly automated workflow
- Mix, store, and dispose of chemical solutions
- Print labels for bottles, vials, and boxes
- Package, seal, inventory, and ship products
- Ensure laboratory products and supplies are maintained and stocked
- Capture production data in compliance with standard guidelines
- Maintaining and perform cleaning to ensure compliant laboratory environment
- Edits manufacturing documents/SOPs as needed to reflect current best practices and current processes.
- Troubleshoots and resolves problems arising from day to day operations.
- Escalate issues that are out of the scope of normal production.
- If necessary, follow up by creating new tickets to log, investigate and/or resolve issues.
- Perform inventory reconciliation
- Practice and drive continuous process improvement with team
- Handle and dispose of hazardous chemicals
Synthego provides tools and services for genetic engineering. It sells synthetic RNA and gene editing reagents that researchers use to modify genes, and it offers a platform that gives users access to advanced gene editing workflows. The products are used by research institutions, pharmaceutical companies, and biotech startups for drug discovery, disease modeling, and genetic research. Unlike competitors that only offer individual components, Synthego combines both physical gene-editing tools and an integrated platform to support end-to-end genetic engineering work. The company’s goal is to help researchers perform gene editing more efficiently and at scale, accelerating discoveries in medicine and agriculture.
Company Size
51-200
Company Stage
Series E
Total Funding
$459.7M
Headquarters
Menlo Park, California
Founded
2012
Simplify's Take
What believers are saying
- Perceptive Advisors acquired Synthego on July 18, 2025, bolstering financial stability.
- Strategic deals with AstraZeneca and HuidaGene expand nuclease portfolio for therapies.
- Dr. Bill Skarnes joined advisory board, enhancing stem cell genome engineering expertise.
What critics are saying
- Perceptive demands cut R&D spending within 6-12 months, eroding innovation edge.
- EditCo Bio spinout diverts talent and clients from core CRISPR business immediately.
- IP disputes in AstraZeneca and HuidaGene licenses halt GMP lines in 12-18 months.
What makes Synthego unique
- Synthego vertically integrates hardware, software, and GMP CRISPR for precise genome engineering.
- Synthego licenses advanced nucleases like hfCas12Max and eSpOT-ON from AstraZeneca and Vita.
- Synthego delivers AccuBase base editors via Base Therapeutics and KACTUS partnerships.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Generous Equity Package
Medical, Dental & Vision
401(k) Plan
Catered to You
Fully Stocked
Transportation
Green Environment
Stay Fit
Legal Ease
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -2%Base Therapeutics and KACTUS announce strategic partnership with Synthego to advance GMP AccuBase(TM) base editing platform. Home / news & articles / Base Therapeutics and KACTUS announce strategic partnership with Synthego to advance GMP AccuBase(TM) base editing platform. Base Therapeutics and KACTUS are excited to announce a strategic partnership with Synthego for the distribution of the AccuBase(TM) cytosine base editor. This collaboration aims to accelerate innovation and accessibility of next-generation cell and gene therapies. This agreement integrates Base Therapeutics' pioneering base-editing technologies, and KACTUS' leadership in enzyme design and GMP-grade production with Synthego's industry-leading RUO-to-GMP CRISPR Solutions to address unmet needs in the rapidly evolving field of genomic medicine. "We are thrilled to collaborate with Synthego and Base Therapeutics to meet the needs of our global customers and accelerate the availability of therapeutic solutions for disease treatment. Through this alliance, we aim to advance the research and industrialization of cell and gene therapy," said Edmund Wang, CEO of KACTUS. Traditional CRISPR editing systems such as Cas9 or Cas12 rely on DNA double-strand breaks, introducing risks such as chromosomal loss or translocation. In contrast, the AccuBase(TM) cytosine base editor represents "CRISPR 2.0" technology that enables ultra-precise, cell-friendly editing with near-zero off-target effects. As the only GMP-grade base editing proteins currently available, AccuBase(TM) marks a new era for gene editing, shifting from "cutting" to "precision modification". "AccuBase(TM) is the next evolution of our clinical-grade solutions, complementing our best-in-class Guide RNA with a powerful base editing platform. With over five years of proven GMP experience and regulatory guidance, we are uniquely positioned to empower our therapeutic partners and accelerate their path to the clinic," said Craig Christianson, CEO of Synthego. "This partnership represents an important milestone in the global expansion of AccuBase(TM). We look forward to working with therapeutic partners to ensure that gene-editing technologies truly benefit human health worldwide," said Dr. Tianhong Xu, Founder and CEO of Base Therapeutics. As a leading supplier in cell and gene therapy, KACTUS provides an extensive portfolio of gene-editing enzymes - including GMP-grade Cas9 (FDA DMF filed) and GMP-grade AccuBase(TM)- to support customers throughout the IND and clinical phases of drug development. By integrating their respective scientific, commercial and regulatory strengths, this strategic partnership will advance the development of next-generation gene editing technologies, establishing a new standard for safe and effective tools in therapeutic applications. About KACTUS. KACTUS is an innovation-driven company specializing in recombinant proteins and enzyme materials to support the development and manufacturing of biopharmaceuticals. Established in 2018, KACTUS has built deep expertise in protein R&D and production through its proprietary structure-designed protein platform, SAMS(TM). With its own 100,000 square foot GMP facility and certified quality system, KACTUS supplies a broad range of GMP-grade raw proteins and enzymes tailored to the needs of cell and gene therapy drug development. About Synthego. Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. Recognized in hundreds of peer-reviewed publications and trusted by thousands of researchers and therapeutic developers, Synthego is driving the future of medicine through cutting-edge genome-editing technologies. About Base Therapeutics. Founded in 2021, Base Therapeutics is a high-tech enterprise focused on breakthrough innovations in gene editing. The company holds more than 30 domestic and international patents and is developing first-in-class cell and gene-editing products, particularly in cancer and rare genetic diseases. Its pipeline includes base-editing CAR-T and in vivo base-editing therapies, as well as NK510 and NK520 programs. Base Therapeutics' NK cell base-editing therapies are already in clinical studies exploring efficacy and safety in relapsed, refractory, and metastatic solid and hematologic tumors where conventional chemotherapy has failed.
Synthego has completed the sale of nearly all its assets to funds managed by Perceptive Advisors, finalized on July 18, 2025. Under Perceptive's ownership, Synthego will continue its operations with the same leadership and brand. The acquisition aims to enhance Synthego's financial position and accelerate innovation in CRISPR solutions. Recent product expansions include a GMP version of SpCas9 and new enzymes, eSpOT-ON and Accubase.
Perceptive Advisors' acquisition of Synthego, a leader in CRISPR solutions, has been cleared to close in July.
Synthego introduced the hfCas12Max CRISPR system in 2024, the first in its portfolio of high-fidelity nucleases designed specifically for therapeutic applications.
REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic programs. This nonexclusive sublicense grants Vita Therapeutics access to the engineered hfCas12Max nuclease and optimized hfCas12Max guide RNAs for use in preclinical and clinical applications, including in potential commercialized therapeutics. "With the integration of hfCas12Max, Vita Therapeutics can accelerate the development of their hypoimmunogenic cell therapies, paving the way for life-changing treatments to reach patients sooner," said Craig Christianson, CEO of Synthego. "Our goal is to make therapeutic CRISPR solutions more accessible by removing traditional bottlenecks with reduced upfront licensing fees and a lower total IP cost as the therapy advances."